A practical reference on trans-3-hexenoyl: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-31. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
== Pathogenic viral fusion == Enveloped viruses readily overcome the thermodynamic barrier of merging two plasma membranes by storing kinetic energy in fusion (F) proteins. F proteins can be independently expressed on host cell surfaces which can either (1) drive the infected cell to fuse with neighboring cells, forming a syncytium, or (2) be incorporated into a budding virion from the infected cell which leads to the full emancipation of plasma membrane from the host cell. Some F components solely drive fusion while a subset of F proteins can interact with host factors. There are four groups of fusion proteins categorized by their structure and mechanism of fusion. Despite their very different structure and presumably different origins, classes I, II, and III all work by forming a trimer of hairpins.
The epidermis is the strong, superficial layer that serves as the first line of protection against the outer environment. The human epidermis is composed of stratified squamous epithelial cells, which further break down into four to five layers: the stratum corneum, stratum granulosum, stratum spinosum and stratum basale. Where the skin is thicker, such as in the palms and soles, there is an extra layer of skin between the stratum corneum and the stratum granulosum called the stratum lucidum. The epidermis is regenerated from the stem cells found in the basal layer that develop into the corneum. The epidermis itself is devoid of blood supply and draws its nutrition from its underlying dermis. Its main functions are protection, absorption of nutrients, and homeostasis. In structure, it consists of a keratinized stratified squamous epithelium; four types of cells: keratinocytes, melanocytes, Merkel cells, and Langerhans cells. The predominant cell keratinocyte, which produces keratin, a fibrous protein that aids in skin protection, is responsible for the formation of the epidermal water barrier by making and secreting lipids. The majority of the skin on the human body is keratinized, with the exception of the lining of mucous membranes, such as the inside of the mouth. Non-keratinized cells allow water to "stay" atop the structure. The protein keratin stiffens epidermal tissue to form fingernails. Nails grow from a thin area called the nail matrix at an average of 1 mm per week.
=== Imaging === Radiological studies of the abdomen, such as CT scans and magnetic resonance imaging are useful for identifying the site of the tumor, differentiating it from other diseases, such as adrenocortical adenoma, and determining the extent of invasion of the tumor into surrounding organs and tissues. On CT, it shows heterogeneous appearance due to necrosis, calcifications, and haemorrhage. After contrast injection, it shows peripheral enhancement. Invasion of adjacent structures such as kidney, vena cava, liver, and retroperitoneal lymph nodes are also common. Online open-access datasets of adrenocortical carcinoma CT examinations are available. On MRI, it shows low intensity on T1-weighted images, and high T2 signal with strong heterogeneous contrast enhancement and slow washout. Haemorrhagic areas may show high T1-signal. Imaging with positron emission tomography (PET) is useful during initial investigation of potentially malignant adrenal tumors and for detecting metastasis. Fluorodeoxyglucose ([18F]FDG or FDG) has high sensitivity but cannot distinguish ACC from other malignancies. 11C-labelled metomidate binds to enzymes expressed in adrenocortical cells and has been used as a radiotracer with high specificity for adrenal tumors.
The Corps were called into action responding to the Castle Hill convict rebellion. Late on 4 March 1804, a great number of rebels rose up at the government farm at Castle Hill, New South Wales, armed themselves with muskets and pikes from surrounding farms, and planned to sack Parramatta and occupy Sydney Town. An alarm at around 11pm raised Major Johnston from his sleep. He then led 29 soldiers of the New South Wales Corps on a forced march from their barracks at Annandale to Parramatta. They arrived around dawn. Later in the morning, with 50 militiamen of the Loyal Volunteers, they pursued the rebels who were now heading to Green Hills, today's Windsor. At a feigned meeting with the rebels aided by a priest as a lure, Johnston took the ringleaders hostage. When they and their men refused to surrender, to the shouts of 'death or liberty' the troops quickly put down the revolt. Over the next three days, repercussions and summary justice reigned. Governor King highly commended Major Johnston for his actions, even though King had to intervene directly to stop a military kangaroo court from hanging one in ten of the rebels. At midnight on 4 March, Captain Daniel Woodriff of HMS Calcutta landed 150 of his crew to assist the New South Wales Corps and Governor King.
=== EC 2.4: glycosyl, hexosyl, and pentosyl transferases === EC 2.4 includes enzymes that transfer glycosyl groups, as well as those that transfer hexose and pentose. Glycosyltransferase is a subcategory of EC 2.4 transferases that is involved in biosynthesis of disaccharides and polysaccharides through transfer of monosaccharides to other molecules. An example of a prominent glycosyltransferase is lactose synthase which is a dimer possessing two protein subunits. Its primary action is to produce lactose from glucose and UDP-galactose. This occurs via the following pathway: UDP-β-D-galactose + D-glucose
Sources: en.wikipedia.org
The second proposed mechanism via an anhydride has similar steps but there is a direct attack of Glu270 on the carbonyl group, and then the interaction of Glu270 on the Zn2+-bound amide forms an anhydride instead which can subsequently be hydrolyzed by water.
Even after slavery became a criminal offense, slave owners could get high returns. According to researcher Siddharth Kara, the profits generated worldwide by all forms of slavery in 2007 were $91.2 billion. That was second only to drug trafficking, in terms of global criminal enterprises. At the time the weighted average global sales price of a slave was estimated to be approximately $340, with a high of $1,895 for the average trafficked sex slave, and a low of $40 to $50 for debt bondage slaves in part of Asia and Africa. The weighted average annual profits generated by a slave in 2007 was $3,175, with a low of an average $950 for bonded labour and $29,210 for a trafficked sex slave. Approximately 40% of slave profits each year were generated by trafficked sex slaves, representing slightly more than 4% of the world's 29 million slaves.
== Articles == Hoyle, F. and Wickramasinghe, N.C., 1962. On graphite particles as interstellar grains, Mon.Not.Roy.Astr.Soc. 124, 417-433 Hoyle, F.; Wickramasinghe, N.C. (1969). "Interstellar Grains". Nature. 223 (5205): 450–462. Bibcode:1969Natur.223..459H. doi:10.1038/223459a0. S2CID 4209522. Wickramasinghe, N. C. (1974). "Formaldehyde polymers in interstellar space". Nature. 252 (5483): 462–463. doi:10.1038/252462a0. ISSN 0028-0836. Retrieved 20 January 2026. Wickramasinghe, N.C. (1999). "Formaldehyde Polymers in Interstellar Space". Astrophysics and Space Science. 268 (1–3): 111–114. doi:10.1023/A:1002448820097. ISSN 0004-640X. Retrieved 20 January 2026. Wickramasinghe, N.C.; Hoyle, F.; Brooks, J.; Shaw, G. (1977). "Prebiotic polymers and infrared spectra of galactic sources". Nature. 269 (5630): 674–676. Bibcode:1977Natur.269..674W. doi:10.1038/269674a0. S2CID 4266722. Hoyle, F. and Wickramasinghe, N.C., 1977. Identification of the λ2,200A interstellar absorption feature, Nature 270, 323-324 F., Hoyle; N. C., Wickramasinghe (4 November 1976). "Primitive grain clumps and organic compounds in carbonaceous chondrites" (PDF). Nature. 264 (5581): 45–46. Bibcode:1976Natur.264...45H. doi:10.1038/264045a0. Retrieved 18 January 2013. Hoyle, F. and Wickramasinghe, N.C., 1977. Polysaccharides and infrared spectra of galactic sources, Nature 268, 610-612 Hoyle, F.; Wickramasinghe, N.C. (1979). "On the nature of interstellar grains". Astrophysics and Space Science. 66 (1–3): 77–90. Bibcode:1999Ap&SS.268..249H. doi:10.1023/A:1002462602776. S2CID 189820472.
=== Further investigations and arrests === Following the verdict, police continued to investigate whether Letby had harmed other infants. Detectives reviewed around 30 cases at the Countess of Chester Hospital that had been identified as "suspicious". Neonatologists examined approximately 4,000 admissions at that hospital, where Letby had worked from 2012, and at Liverpool Women's Hospital, where she had completed two placements in 2012 and 2015, and were asked to refer any "unexpected and unexplained" deteriorations to police. At least one family was informed that their child's case at Liverpool Women's Hospital formed part of the inquiry. Cheshire Police interviewed Letby under caution in relation to deaths at both hospitals. On 2 July 2025, the Crown Prosecution Service confirmed that it was considering further charges based on new evidence provided by the police. On 20 January 2026, after reviewing evidence relating to allegations of murder involving two children and attempted murder involving seven others, the Crown Prosecution Service announced that no further charges would be brought against Letby. On 4 October 2023, Cheshire Constabulary announced an investigation into potential corporate manslaughter at the Countess of Chester Hospital. On 1 July 2025, three members of the hospital's former senior leadership team were arrested on suspicion of gross negligence manslaughter. On 22 April 2026 one of the three was arrested and bailed for perverting the course of justice.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.